Glenmark’s FabiFlu Shows Promise for COVID-19 Patients

Glenmark Pharmaceuticals’ favipiravir helped patients with mild to moderate COVID-19 infections recover more quickly, according to early data from a phase 3 trial.

The study in 150 patients found that those treated with the drug shook off the virus 28.6 percent faster than those who did not receive the treatment.

The drug was generally well tolerated, with no serious adverse events or deaths in those treated with favipiravir, the company said.